ERBB2 and neoplasm: Current experimental techniques are biased towards the identification of shared tumor antigens such as HER2/neu [39,40], MUC1 [41], and mammaglobin-A [42-44], and no experimental techniques are capable of rapidly or systematically identifying unique tumor antigens.